Liu Yong-Zhong, Chen Bin, She Xi-Dian
World J Gastroenterol. 1998 Jun;4(3):225-227. doi: 10.3748/wjg.v4.i3.225.
To investigate the correlation between the serum soluble intercellular adhesion molecule-1 (sICAM-1) and the clinicopathologic features and to evaluate the possible prognostic significance of sICAM-1 concentration in gastric cancer.METHODS: Thirty-four patients with gastric cancer were prospectively included and evaluated. Venous blood samples were collected before the surgery. Sera were obtained by centrifugation, and store at -30 degree until assay. The control group consisted of 20 healthy volunteers. Serum concentrations of ICAM-1 were measured with the quantitative sandwich enzyme immunoassay technic. Differences between the two groups were analyzed by Student's t test. x+2s of normal control sICAM-1 was taken as upper limit to calculate the positive rates.RESULTS:The mean value of serum ICAM-1 in patients with gastric cancer was 367.7&mgr;g/L plus minus 104.7&mgr;g/L and that of control group was 236.9&mgr;g/L plus minus 74.3&mgr;g/L, and the difference was significant (P < 0.001). The patients with tumor size of > = 5cm had significantly higher serum concentrations of sICAM-1 than those with smaller ones (406.7&mgr;g/L plus minus 90.2&mgr;g/L vs 319.9&mgr;g/L plus minus 105.3&mgr;g/L,P <0.01). Compared with stages I-II gastric cancer patients, patients with more advanced clinical stage (III-IIV) had higher levels of sICAM-1 (397.1&mgr;g/L plus minus 102.4&mgr;g/L vs 306.0&mgr;g/L plus minus 82.3&mgr;g/L,P <0.05).Difference was significant statistically in sICAM-1 levels between patients with positive lymph node status and those without lymph node involvement (403.6&mgr;g/L plus minus 99.7&mgr;g/L vs 302.7&mgr;g/L plus minus 81.4&mgr;g/L,P <0.01). No relation was observed between the level of sICAM-1 and grade of histological differentiation in the patients with gastric cancer.CONCLUSION:Serum sICAM-1 concentration may be a valuable parameter for predicting the prognosis and degree of the gastric cancer.
探讨血清可溶性细胞间黏附分子-1(sICAM-1)与胃癌临床病理特征之间的相关性,并评估sICAM-1浓度在胃癌中可能的预后意义。方法:前瞻性纳入并评估34例胃癌患者。术前采集静脉血样本。通过离心获得血清,并在-30℃保存直至检测。对照组由20名健康志愿者组成。采用定量夹心酶免疫分析技术测定血清ICAM-1浓度。两组间差异采用Student's t检验分析。以正常对照组sICAM-1的x+2s作为上限计算阳性率。结果:胃癌患者血清ICAM-1的平均值为367.7μg/L±104.7μg/L,对照组为236.9μg/L±74.3μg/L,差异有统计学意义(P<0.001)。肿瘤大小≥5cm的患者血清sICAM-1浓度显著高于肿瘤较小的患者(406.7μg/L±90.2μg/L对319.9μg/L±105.3μg/L,P<0.0)。与Ⅰ-Ⅱ期胃癌患者相比,临床分期较晚(Ⅲ-Ⅳ期)的患者sICAM-1水平更高(397.1μg/L±102.4μg/L对306.0μg/L±82.3μg/L,P<0.05)。有淋巴结转移阳性患者与无淋巴结转移患者的sICAM-1水平差异有统计学意义(403.6μg/L±99.7μg/L对302.7μg/L±81.4μg/L,P<0.01)。在胃癌患者中,未观察到sICAM-1水平与组织学分化程度之间的关系。结论:血清sICAM-1浓度可能是预测胃癌预后和程度的一个有价值的参数。